ArticleDrug safety2025
Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Glatiramer Acetate Therapy: An Extended 4-Year Safety Update.
Article in Drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging the Pregnancy Knowledge Gap: A Real-World Analysis of Medication Use and Drug-Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis.Clinical and translational science · 2026Article
- Cumulative six-year safety outcomes of glatiramer acetate exposure during pregnancy and breastfeeding.Journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesWhile glatiramer acetate (GA) is generally considered safe during pregnancy and breastfeeding, long-term data, particularly for the 40 mg/mL dose, are limited. Previous research found GA exposure rates and pregnancy outcomes comparable to the general population. This study evaluates pregnancy, fetal, and infant outcomes following maternal exposure to GA 20 and 40 mg/mL to provide a cumulative four-year update.
methodsPost-marketing pregnancy data reported between April 1, 2019 to March 31, 2023 were searched in Teva's Global Safety database and supplemented with 1- and 12-month post-delivery questionnaires. Prospective pregnancy data, collected prior to known pregnancy outcomes or congenital malformations, were used to estimate pregnancy and infant outcomes for GA 20 and 40 mg/mL exposure. Rates of major congenital malformations (MCM) and other pregnancy and infant outcomes were estimated.
resultsAmong 3514 pregnancies, multiple sclerosis (MS) was the primary indication (62.4%), with most exposure to GA 40 mg/mL (72.2%), in the first trimester (94.9%). Of these, 2455 (69.9%) had known pregnancy outcomes. Of 1211 prospective pregnancies (1239 fetuses) with known outcomes, 1138 (91.8%) resulted in live births. Fetal loss occurred in 101 cases (8.2%), including spontaneous abortion (6.7%), elective termination (0.8%), ectopic pregnancy (0.3%), stillbirth (0.2%), and other (0.2%). The prevalence of MCM was 1.5% overall (95% CI, 0.9-2.4) and 1.9% during organogenesis (95% CI, 1.1-3.1), comparable to background rates. Minor congenital malformations were less frequent (0.7%). Prospective pregnancies with completed questionnaires (n = 539) reported preterm birth (9.8%), low/very low birth weight (7.3%), neonatal intensive care unit (NICU) admission (8.8%), and adverse events (17.4%). Infant growth remained within normal ranges. Of 384 women completing the 12-month questionnaire, 146 reported breastfeeding with GA (average 8 months). Among these, 14/125 (11.2%) respondents reported infant hospitalization. Growth parameters for 55 breastfed infants were within normal limits. Overall, pregnancy and infant outcomes were similar across GA doses. DISCUSSION: Despite limitations of post-marketing data, this four-year study found no increased risk of adverse pregnancy, fetal, or infant outcomes associated with GA exposure. The MCM rates aligned with the general population, and infant outcomes during breastfeeding were within normal ranges. These findings support the safety of both 20 and 40 mg/mL GA during pregnancy and breastfeeding.
Indexed as
Identifiers
40106171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.